.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Fuji
US Department of Justice
Moodys
US Army
Teva
Covington
Cipla
Julphar
Mallinckrodt

Generated: November 22, 2017

DrugPatentWatch Database Preview

TEVETEN HCT Drug Profile

« Back to Dashboard

Which patents cover Teveten Hct, and when can generic versions of Teveten Hct launch?

Teveten Hct is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in TEVETEN HCT is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.

Pharmacology for TEVETEN HCT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
TEVETEN HCT
eprosartan mesylate; hydrochlorothiazide
TABLET;ORAL021268-001Nov 1, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbvie
TEVETEN HCT
eprosartan mesylate; hydrochlorothiazide
TABLET;ORAL021268-002Nov 1, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TEVETEN HCT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
TEVETEN HCT
eprosartan mesylate; hydrochlorothiazide
TABLET;ORAL021268-001Nov 1, 2001► Subscribe► Subscribe
Abbvie
TEVETEN HCT
eprosartan mesylate; hydrochlorothiazide
TABLET;ORAL021268-002Nov 1, 2001► Subscribe► Subscribe
Abbvie
TEVETEN HCT
eprosartan mesylate; hydrochlorothiazide
TABLET;ORAL021268-002Nov 1, 2001► Subscribe► Subscribe
Abbvie
TEVETEN HCT
eprosartan mesylate; hydrochlorothiazide
TABLET;ORAL021268-001Nov 1, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Queensland Health
Mallinckrodt
Farmers Insurance
US Department of Justice
Fish and Richardson
Express Scripts
Teva
Baxter
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot